{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Cardio-esophageal+Junction+of+Stomach&page=2", "query": { "condition": "Malignant Neoplasm of Cardio-esophageal Junction of Stomach", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignant+Neoplasm+of+Cardio-esophageal+Junction+of+Stomach&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T07:37:05.439Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Volrustomig", "type": "BIOLOGICAL" }, { "name": "Rilvegostomig", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 450, "start_date": "2020-06-03", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-07-10", "last_synced_at": "2026-07-24T07:37:05.439Z", "location_count": 10, "location_summary": "Santa Monica, California • Westwood, Kansas • Baltimore, Maryland + 6 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04379596" }, { "nct_id": "NCT04220827", "title": "Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Peritoneal Carcinomatosis", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2019-12-06", "completion_date": "2028-10-30", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-07-24T07:37:05.439Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04220827" }, { "nct_id": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2-positive Solid Tumors", "HER2-positive Breast Cancer", "HER2-positive Colorectal Cancer", "HER2-positive Gastroesophageal Cancer", "HER2-positive Endometrial Cancer" ], "interventions": [ { "name": "BDC-1001", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bolt Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2020-02-24", "completion_date": "2025-02-14", "has_results": false, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-07-24T07:37:05.439Z", "location_count": 11, "location_summary": "Palo Alto, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04278144" }, { "nct_id": "NCT03798626", "title": "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer", "Gastroesophageal Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "Gevokizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Modified FOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 167, "start_date": "2019-05-22", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2026-04-01", "last_synced_at": "2026-07-24T07:37:05.439Z", "location_count": 3, "location_summary": "Los Angeles, California • St Louis, Missouri • Nashville, Tennessee", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03798626" }, { "nct_id": "NCT02586987", "title": "A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer", "Melanoma", "Head and Neck Carcinoma", "Gastroesophageal Cancer", "Breast Cancer", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Biliary Tract Cancer" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "MEDI4736", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 58, "start_date": "2015-12-28", "completion_date": "2019-09-20", "has_results": false, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-07-24T07:37:05.439Z", "location_count": 6, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02586987" }, { "nct_id": "NCT02855788", "title": "Metronomic Chemotherapy in Advanced Gastric Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Gastric Cancer", "Locally Advanced Gastric Cancer" ], "interventions": [ { "name": "Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Huashan Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2015-05", "completion_date": "2018-10", "has_results": false, "last_update_posted_date": "2016-08-04", "last_synced_at": "2026-07-24T07:37:05.439Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02855788" }, { "nct_id": "NCT00539617", "title": "Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2007-10-05", "completion_date": "2011-05-12", "has_results": true, "last_update_posted_date": "2020-03-23", "last_synced_at": "2026-07-24T07:37:05.439Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00539617" }, { "nct_id": "NCT04504669", "title": "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clear Cell Renal Cell Cancer", "Non-Small-Cell Lung Cancer", "Triple Negative Breast Neoplasms", "Squamous Cell Cancer of Head and Neck", "Small Cell Lung Cancer", "Gastroesophageal Cancer", "Melanoma", "Cervical Cancer", "Advanced Solid Tumours" ], "interventions": [ { "name": "AZD8701", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 60, "start_date": "2020-08-18", "completion_date": "2024-10-07", "has_results": false, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-07-24T07:37:05.439Z", "location_count": 6, "location_summary": "Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Franklin", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04504669" }, { "nct_id": "NCT00524186", "title": "Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "sunitinib malate", "type": "DRUG" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 23, "start_date": "2007-05", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-06-21", "last_synced_at": "2026-07-24T07:37:05.439Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524186" }, { "nct_id": "NCT03829436", "title": "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma", "Metastatic Castration Resistant Prostate Cancer", "Renal Cell Carcinoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Squamous Cell Carcinoma of Head and Neck", "Triple-Negative Breast Cancer", "Urothelial Carcinoma", "Cholangiocarcinoma", "GastroEsophageal Cancer", "Pancreatic Cancer", "Sarcoma" ], "interventions": [ { "name": "Part 1 TPST-1120", "type": "DRUG" }, { "name": "Part 2 TPST-1120 + nivolumab", "type": "DRUG" }, { "name": "Part 3 TPST-1120", "type": "DRUG" }, { "name": "Part 4 TPST-1120 + nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tempest Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2019-03-20", "completion_date": "2022-09-07", "has_results": false, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-07-24T07:37:05.439Z", "location_count": 11, "location_summary": "San Francisco, California • Miami, Florida • Baltimore, Maryland + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03829436" } ] }